Discovery of Benzopyridone-Based Transient Receptor Potential Vanilloid 1 Agonists and Antagonists and the Structural Elucidation of Their Activity Shift

J Med Chem. 2021 Jan 14;64(1):370-384. doi: 10.1021/acs.jmedchem.0c00982. Epub 2021 Jan 1.

Abstract

Among a series of benzopyridone-based scaffolds investigated as human transient receptor potential vanilloid 1 (TRPV1) ligands, two isomeric benzopyridone scaffolds demonstrated a consistent and distinctive functional profile in which 2-oxo-1,2-dihydroquinolin-5-yl analogues (e.g., 2) displayed high affinity and potent antagonism, whereas 1-oxo-1,2-dihydroisoquinolin-5-yl analogues (e.g., 3) showed full agonism with high potency. Our computational models provide insight into the agonist-antagonist boundary of the analogues suggesting that the Arg557 residue in the S4-S5 linker might be important for sensing the agonist binding and transmitting signals. These results provide structural insights into the TRPV1 and the protein-ligand interactions at a molecular level.

Publication types

  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Drug Discovery*
  • Humans
  • Molecular Structure
  • Pyridones / chemistry*
  • Structure-Activity Relationship
  • TRPV Cation Channels / agonists*
  • TRPV Cation Channels / antagonists & inhibitors*
  • Urea / chemistry

Substances

  • Pyridones
  • TRPV Cation Channels
  • TRPV1 protein, human
  • Urea